F-star Biotechnology

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.
Type
Private
HQ
Cambridgeshire, GB
Founded
2006
Employees
62 (est)+2%
F-star Biotechnology was founded in 2006 and is headquartered in Cambridgeshire, GB

Key People at F-star Biotechnology

Eugen Stermetz

Eugen Stermetz

CFO
Kevin FitzGerald

Kevin FitzGerald

CEO
John Haurum

John Haurum

CEO
Jane Dancer

Jane Dancer

coo

F-star Biotechnology Locations

Cambridgeshire, GB
Wien, AT

F-star Biotechnology Metrics

F-star Biotechnology Summary

Founding Date

2006

Total Funding

$57.3 M

Latest funding size

$9.4 M

Time since last funding

about 3 years

Investors

F-star Biotechnology's latest funding round of $9.4 M was in October 2013. In total, F-star Biotechnology has raised $57.3 M.
24% of current employees of F-star Biotechnology are female and 76% are male.

F-star Biotechnology News

F-star Biotechnology Company Life

You may also be interested in